The other siblings: Respiratory infections caused by Moraxella catarrhalis and Haemophilus influenzae

Current Infectious Disease Reports

Volumn 8, Issue 3, 2006, Pages 215-221

  Lutwick, Larry ^a   Fernandes, Laila ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL VACCINE; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MACROLIDE; METICILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULBACTAM; TETANUS TOXOID; TETRACYCLINE;

ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOTYPE; BRAZIL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEVELOPING COUNTRY; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENZYME INHIBITION; FEVER; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; INFLUENZA; LARYNGITIS; MORAXELLA CATARRHALIS; NONHUMAN; PATHOGENESIS; RESPIRATORY TRACT INFECTION; SIBLING; UPPER RESPIRATORY TRACT INFECTION;

EID: 33646809770     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-006-0062-0     Document Type: Article

References (49)

1. Berger U: Die anspruchslosen Neisserien. Ergeb Microbiol Immunitaetforsh 1963, 36:97-167.
2. Catlin BW: Transfer of the organism named Neisseria catarrhalis to Branhamella gen. nov. Int J Syst Bacteriol 1970, 20:150-159.
3. Bovre K: The genus moraxella, In Bergey's Manual of Systematic Bacteriology, vol 1. Edited by, Krieg NR, Hold JG. Baltimore: Williams & Wilkins; 2000:296-303.
4. Verduin CM, Hol C, Fleer A, et al.: Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 2002, 15:125-144.
5. Murphy TF: Branhamella catarrhalis: epidemiological and clinical aspects of a human respiratory tract pathogen. Thorax 1998, 53:124-128.
6. Faden H, Harabuchi Y, Hong JJ: Epidemiology of moraxella catarhalis in children during the first 2 years of live: relationship to otitis media. J Infect Dis 1994, 169:1312-1317.
7. Abuhammour WM, Abdel-Haq M, Asmar BI, Dajani AS: Moraxella catarrhalis bacteremia: a 10-year experience. South Med J 1999, 92:1071-1074.
8. Wallace MR, Oldfield C: Moraxella (Branhamella) catarrhalis bacteremia: a case report and literature review. Arch Intern Med 1990, 150:1332-1334.
9. Blumer J: Clinical perspectives on sinusitis and otitis media. Pediatr Infect Dis 1998, 17(Suppl 8):S68-S72.
10. Patel JA, Reisner B, Vizirinia N, et al.: Bacteriologic failure of amoxicillin-clavulanate in the treatment of acute otitis media caused by nontypeable Haemophilus influenzae. J Pediatr 1995, 126:799-706.
11. Faden H, Bernstein L, Brodsky J, et al.: Effect of prior antibiotic treatment on middle ear disease in children. Ann Otol Rhinol Laryngol 1992, 101:87-91.
12. Boyle FM, Georghiou PR, Tilse MH, McCormack JG: Branhamella (Moraxella) catarrhalis: pathogenic significance in respiratory infections. Med J Aust 1991, 154:592-596.
13. Berg RA, Bartley DL: Pneumonia associated with Branhamella catarrhalis in infants. Pediatr Infect Dis 1987, 6:569-573.
14. Hol C, Schalen C, Verduin CM, et al.: Moraxella catarrhalis in acute laryngitis: infection or colonization? J Infect Dis 1996, 174:636-668.
15. Vaneechoutte M, Verschraegen G, Claeys G, et al.: Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum. J Clin Microbiol 1990, 28:2674-2680.
16. Wright PW, Wallace RJ, Shepherd JR: A descriptive study of 42 cases of Branhamella catarrhalis pneumonia. Am J Med 1990, 88:2S-8S.
17. Hager H, Verghese A, Alvarez S, Berk SL: Branhamella catarrhalis respiratory infections. Rev Infect Dis 1987, 9:1140-1149.
18. Irwin RS, Woelk WK, Coudon WL: Primary meningococcal pneumonia. Ann Intern Med 1975, 82:493-498.
19. Patterson TF, Patterson JE, Masecar BL, et al.: A nosocomail outbreak of Branhamella catarrhalis confirmed by restriction endonuclease analysis. J Infect Dis 1988, 157:996-1001.
20. Ikram RB, Nixon M, Aitken J, Wells E: A prospective study of isolation of Moraxella catarrhalis in a hospital during the winter months. J Hosp Infect 1993, 25:7-14.
21. Calder MA, Croughan MJ, McLeod DT, Ahmad F: The incidence and antibiotic susuceptibility of Branhamella catarrhalis in respiratory infections. Drugs 1986, 31 (Suppl 3):11-16.
22. Watanabe H, Hoshino K, Sugita R, et al.: Molecular analysis of intrafamiliar transmission of Moraxella catarrhalis. Int J Med Microbiol 2005, 295:187-191.
23. McMichael JC: Vaccines for Moraxella catarrhalis. Vaccine 2001, 19:S101-S107.
24. Murphy TF: Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Expert Rev Vaccines 2005, 4:843-853.
25. Turk DC: Clinical importance of Haemophilus influenzae. In Haemophilus Influenzae, Epidemiology, Immunology, and Prevention of Disease. Edited by Sell SH, Wright PF. Elsevier: New York; 1982:3-9.
26. Samuelson A, Freijd A, Jonasson J, Lingberg AA: Turnover of nonencapsulated Haemophilus influenzae in the nasopharynges of otitis-prone children. J Clin Microbiol 1995, 33:2027-2031.
27. Anderson P, Johnston R, Smith DH: Human serum activities against Haemophilus influenzae type b. J Clin Invest 1972, 51:31-38.
28. Lutwick LI: Infections in asplenic patients. In Mandell, Douglas and Bennett's Perinciples and Practice of Infectious Diseases, edn 6. Edited by Mandell GL, Bennett JE, Dolin R. Churchill Livingstone: Philadelphia; 2005:3524-3532.
29. McVernon J, Slack MP, Ramsay ME: Changes in the epidemiology of epiglottitis following introduction of Haemophilus influenzae type b (Hib) conjugate vaccines in England: a comparison of two data sources. Epidemiol Infect 2005, 17:1-3.
30. Wood N, Menzies R, McIntyre P: Epiglottitis in Sydney before and after the introduction of vaccination against Haemophilus influenzae type b disease. Intern Med J 2005, 35:530-535.
31. Peltola H: Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000, 13:302-317.
32. Lehmann D: Epidemiology of acute respiratory tract infections, especially those due to Haemophilus influenzae, in Papua New Guinean children. J Infect Dis 1992, 165:S185-S189.
33. Mulholland E, Alexander ER, Pepe M, et al.: Randomised trial of Haemophilus influenze type-b tetanus protein conjugate vaccine prevention of pneumonia and meninigitis in Gambian infants. Lancet 1997, 349:1191-1197.
34. Shann F: Haemophilus influenzae pneumonia: type b or non-type b? Lancet 1999, 354:1488-1490.
35. Furrer M, Cottagnoud P, Muhlemann K: Haemophilus influenzae infections among hospitalized adult patients. Infection 2000, 28:351-354.
36. American Academy of Pediatrics: Haemophilus influenzae infections. In Red Book: 2003 Report of the Committee on Infectious Diseases, edn 26. Edited by Pickering LK. Elk Grove Village, IL: American Academy of Pediatrics; 2003:296.
37. Bath S, Biskard K, Murphy T, et al.: Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children-United States, 1998-2000. Morbid Mortal Wkly Rep 2002, 51:234-237.
38. St. Geme JW: The pathogenesis of nontypable Haemophilus influenzae otitis media. Vaccine 2001, 19:S41-S50.
39. Shann F, Germer S, Hazlett D: Aetiology of pneumonia in children in Goroka Hospital, Papua New Guinea. Lancet 1994, 2:537-541.
40. Wall RA, Corrah PT, Mabey DCW, Greenwood BM: The etiology of lobar pneumonia in the Gambia. Bull World Health Org 1986, 64:553-558.
41. Adegbola RA, Falade AG, Sam BE, et al.: The etiology of pneumonia in malnourished and well-nourished Gambian children. Pediatr Infect Dis J 1994, 13:975-982.
42. Bandi V, Jakubowycz M, Kinyon C, et al.: Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol 2003, 37:69-75.
43. Gu X-X, Rudy SF, Chu C, et al.: Phase I study of a lipooligosaccharide-based conjugate vaccine against nontypeable Haemophilus influenzae. Vaccine 2003, 21:2107-2114.
44. Sabirov A, Kodama S, Sabirova N, et al.: Intranasal immunization with outer membrane protein P6 and cholera toxin induces sinus mucosal immunity and enhances sinus clearance of nontypeable Haemophilus influenzae. Vaccine 2004, 22:3112-3121.
45. Brazilian Purpuric Fever Study Group: Brazilian purpuric fever: epidemic purpura fulminans associated with antecedent purulent conjunctivitis. Lancet 1987, 2:757-761.
46. Harrison LH, da Silva GA, Pittman M, et al.: Epidemiology and clinical spectrum of Brazilian purpuric fever. J Clin Microbiol 1989, 27:599-604.
47. Kroll JS, Farrant JL, Tyler S, et al.: Characterisation and genetic organization of a 24-Mda plasmid from the Brazilian Purpuric Fever clone of Haemophilus influenzae biogroup aegyptius. Plasmid 2002, 48:38-48.
48. McGillivary G, Tomaras AP, Rhodes ER, Actis LA: Cloning and sequencing of a genomic island found in the Brazilian purpuric fever clone of Haemophilus influenzae biogroup aegyptius. Infect Immun 2005, 73:1927-1938.
49. Peters VB, Rubim LG: Antibodies to lipoligosaccharide of a Brazilian Purpuric Fever isolate of Haemophilus influenzae biogroup aegyptius lack Bactericidal and protective activity. Infect Immun 1992, 60:3423-3427.